Novo Holdings Announces Investment in SCHOTT Poonawalla to Accelerate Growth and Innovation in Injectable Drug Packaging
SINGAPORE, May 14, 2025 /PRNewswire/ -- Novo Holdings, a global life sciences investor, today announced its investment in SCHOTT Poonawalla, India's leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals, alongside TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG.
SCHOTT Poonawalla is a joint venture between SCHOTT Pharma AG and the Serum Institute of India and is recognised as India's foremost manufacturer of injectable-focused primary packaging, offering a full range of products including ampoules, vials, cartridges, and prefilled syringes. The company serves over 100 pharmaceutical customers and operates three manufacturing facilities across India with a capacity of over 3 billion units annually.
This investment underscores Novo Holdings' commitment to building long-term partnerships with differentiated healthcare platforms in Asia and further strengthens its presence in the pharmaceutical infrastructure segment. It also marks Novo Holdings' first investment in the Medtech manufacturing space in India and aligns with its strategy to back category-defining life sciences platforms globally. Novo Holdings will continue to support the company's expansion through value creation initiatives and long-term engagement.
"Our investment in SCHOTT Poonawalla reflects our conviction in the strategic importance of high-quality drug delivery systems and the critical role India plays in the global pharmaceutical supply chain," said Amit Kakar, Managing Partner and Head of Asia at Novo Holdings. "We look forward to supporting SCHOTT Poonawalla's next phase of growth alongside TPG and SCHOTT Pharma and help expand its global footprint while ensuring resilient and sustainable supply of essential packaging solutions."
"SCHOTT Poonawalla is a clear market leader in India's injectable packaging space, with a strong reputation for quality, innovation, and reliability," added Navjeewan Khosla, Partner at Novo Holdings Asia. "We see significant opportunity to add value by leveraging Novo Holdings' life sciences network, experience in Medtech, and strong global partnerships across the biopharma industry."
About SCHOTT Poonawalla
SCHOTT Poonawalla is one of India's leading experts for premium parenteral packaging systems made from tubular glass and cater to the pharmaceutical industry with an extensive product portfolio of vials, pre-fillable syringes, ampoules and cartridges. Established in 1990 as a premium manufacturer of tubular glass pharmaceutical containers, we are a 50-50 joint venture partner with SCHOTT Pharma AG & Co. KGaA, Germany, an international technology group and one of the world's leading experts in glass parenteral packaging, headquartered in Mainz, Germany. At SCHOTT Poonawalla, we care deeply about our responsibility to our employees, society, and the environment.
About Novo Holdings
Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion.
SOURCE Novo Holdings
Share this article